Metabolic disorders in prediabetes: From mechanisms to therapeutic management

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

1552

Figures (1-4)

Tables (1-8)

132

Sum=1847

Publishing Process of This Article

Item

Count

Browse

Download

131

Sum=201

Mar 15, 2024 (publication date) through Jul 21, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Mar 15, 2024; 15(3): 361-377
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361

Table 6 Types of Sodium–glucose cotransporter 2 inhibitors and their recommended clinical dosage

Name	Molecular formula	Recommended initial dosage	In China, Listed or not	Recommended dosage for prediabetes	Ref.
Canagliflozin	C₂₄H₂₅FO₅S	100 mg/day	No	–	–
Dapagliflozin	C₂₁H₂₅CIO₆•C₃H₈O₂	5 mg/day	Listed	10 mg/day	Lundkvist et al[63]
Empagliflozin	C₂₃H₂₇CIO₇	10 mg/day	No	10 mg/day	Lee et al[64]
Ipragliflozin	C₂₁H₂₁FO₅S	50 mg/day	No	–	–
Luseogliflozin	C₂₃H₃₀O₆S	2.5 mg/day	No	–	–
Tofogliflozin	C₂₂H₂₆O₆	5 mg/day	No	40 mg/day	Pafili et al[65]

Citation: Ping WX, Hu S, Su JQ, Ouyang SY. Metabolic disorders in prediabetes: From mechanisms to therapeutic management. World J Diabetes 2024; 15(3): 361-377
URL: https://www.wjgnet.com/1948-9358/full/v15/i3/361.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i3.361